Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: A phase II trial

Leukemia and Lymphoma

Volumn 50, Issue 2, 2009, Pages 216-222

  Blanes, Margarita ^a,b   de la Rubia, Javier ^a   Lahuerta, Juan J ^c   Gonzalez, Jose ^d   Ribas, Paz ^e   Solano, Carlos ^f   Alegre, Adrian ^g   Sanz, Miguel A ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^e HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^g HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Autologous; Intravenous busulfan; Multiple myeloma; Toxicity; Transplantation

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; BUSULFAN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; PREDNISONE; STEROID; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BACTEREMIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; LIVER DISEASE; LIVER TOXICITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEIZURE; SEPTIC SHOCK; SINUSOIDAL OCCLUSIVE SYNDROME; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; AGED; BUSULFAN; CELL MOVEMENT; CELL SEPARATION; DISEASE PROGRESSION; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 61349147901     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802630170     Document Type: Article

References (32)

1. Attal, M., Harousseau, J. L., Stoppa, A. M., Sotto, J. J., Fuzibet, J. G. Rossi, J. F. et al. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med, 335, pp. 91-97.
2. Child, J. A., Morgan, G. I., Davies, F. E., Owen, R. G., Bell, S. E. Hawkins, K. et al. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med, 348, pp. 1875-1883.
3. Harousseau, J. L., Moreau, P., Attal, M., Facon, T. and Avet-Loiseau, H. (2005) Stem-cell transplantation in multiple myeloma. Best Pract Res Clin Haematol, 18, pp. 603-618.
4. Kyle, R. A. (2005) Five decades of therapy for multiple myeloma: A paradigm for therapeutic models. Leukemia, 19, pp. 910-912.
5. Barlogie, B., Jagannath, S., Vesole, D., Naucke, S., Cheson, B. Mattox, S. et al. (1998) Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant, 21, pp. 1101-1107.
6. Moreau, P., Facon, T., Attal, M., Hulin, C., Michallet, M. Maloisel, F. et al. (2002) Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood, 99, pp. 731-735.
7. Mansi, J., Da Costa, F., Viner, C., Judson, J., Gore, M. and Cunnigham, D. (1992) High-dose busulfan in patients with myeloma. J Clin Oncol, 10, pp. 1569-1573.
8. Alegre, A., Lamana, M., Arranz, R., Fernandez-Villa, M. J., Tomas, J. F. Figuera, A. et al. (1995) Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. Br J Haematol, 91, pp. 380-386.
9. Bensinger, W. I., Rowley, S. D., Demirer, T., Lilleby, K., Schiffman, K. Chauncey, T. et al. (1996) High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol, 145, pp. 1447-1456.
10. Benson, D. M., Elder, P. J., Lin, T. S., Blum, W., Penza, S. Avalos, B. et al. (2007) High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimen for autologous stem cell transplantation in patients with multiple myeloma. Leuk Res, 31, pp. 1069-1075.
11. Anderson, K. C., Shaughnessy, J. D., Barlogie, B., Harousseau, J. L. and Rodman, G. D. (2002) Multiple myeloma. Hematology (Am Soc Hematol Educ Program), 21, pp. 4-40.
12. Lahuerta, J. J., Martinez, J., Grande, C., Blade, J., de la Serna, J. Alegre, A. et al. (2000) Conditioning regimens in autologous stem cell transplantation for multiple myeloma: A comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in multiple myeloma. Br J Haematol, 109, pp. 138-147.
13. Carrera, E., Rosinol, L., Terol, M. J., Alegre, A., de Arriba, F. Garcia-Larana, J. et al. (2007) Spanish Myeloma Group/PETHEMA. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant, 13, pp. 1448-1454.
14. Shimoni, A., Bicliorai, B., Toren, A., Hardan, I., Avigdor, A. Yeshurun, M. et al. (2003) Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation. Myeloablation with reduced toxicity. Exp Hematol, 31, pp. 428-434.
15. Kashyap, A., Wingard, J., Cagnoni, P., Tarantolo, S., Hu, W. Blume, K. et al. (2002) Intravenous versus oral busulfan as part of busulfan/ cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant, 8, pp. 493-500.
16. Andersson, B. S., Ashyap, A., Gian, V., Wingard, J., Fernandez, H. Cagnoni, P. et al. (2002) Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study. Biol Blood Marrow Transplant, 8, pp. 145-154.
17. Aggarwal, C., Gupta, S., Vaughan, W. P., Saylors, G. B., Salzman, D. E. Katz, R. O. et al. (2006) Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant, 12, pp. 770-777.
18. Kebriaei, P., Giralt, S., Madden, T., Thapar, N., Shpall, E. Hosing, C. et al. (2006) Toxicity and early response after intravenous (IV) busulfan (Bu) plus melphalan (Mel) conditioning for autologous stem cell transplantation (SCT) in patients (pts) with multiple myeloma (MM). Blood, 108, p. 2943a.
19. Fernandez, H. F., Tran, H. T., Albrecht, F., Lennon, S., Caldera, H. and Goodman, M. S. (2002) Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant, 8, pp. 486-492.
20. Russell, J. A., Tran, H. T., Quinlan, D., Chaudhry, A., Duggan, P. Brown, C. et al. (2002) Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant, 8, pp. 468-476.
21. Bearman, S. I., Appelbaum, F. R., Buckner, C. D., Petersen, F. B., Fisher, L. D. Clift, R. A. et al. (1988) Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol, 6, pp. 1562-1568.
22. Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B. Gharton, G. et al. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol, 102, pp. 1115-1123.
23. Cavo, M., Tosi, P., Zamagni, E., Cellini, C., Tacchetti, P. Patriarca, F. et al. (2007) Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol, 25, pp. 2434-2441.
24. Kyle, R. A. and Rajkumar, S. V. (2004) Multiple myeloma. N Engl J Med, 351, pp. 186-173.
25. Reich, G., Mapara, M. Y., Reichardt, P., Dorken, B. and Maschmeyer, G. (2001) Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: Comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant, 27, pp. 525-529.
26. Auner, H. W., Sill, H., Mulabecirovic, A., Linkesch, W. and Krause, R. (2002) Infectious complications after autologous hematopoietic stem cell transplantation: Comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma. Ann Hematol, 81, pp. 374-377.
27. Puig, N., de la Rubia, J., Jarque, I., Salavert, M., Montesinos, P. Sanz, J. et al. (2007) A study of incidence and characteristics of infections in 476 patients from a single center undergoing autologous blood stem cell transplantation. Int J Hematol, 86, pp. 186-192.
28. Kolbe, K., Domkin, D., Derings, H. G., Bhakdi, S., Huber, C. Aulitzky, W. E. et al. (1997) Infections complications during neutropenia subsequent peripheral blood stem cell transplantation. Bone Marrow Transplant, 19, pp. 143-147.
29. Offidani, M., Corvatta, L., Olivieri, A., Rupoli, S., Frayfer, J. Mele, A. et al. (1999) Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. Bone Marrow Transplant, 24, pp. 1079-1087.
30. Durie, B. (2005) New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals. Clin Lymphoma Myeloma, 6, pp. 181-190.
31. Attal, M., Harousseau, J. L., Facon, T., Guilhot, E., Doyen, C. Fuzibet, J. G. et al. (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med, 349, pp. 2495-2502.
32. Barlogie, B., Tricot, G., Anaisie, E., Shaughnessy, J., Rasmissen, E. Van Rhee, F. et al. (2006) Thalidomide and hematopoietic cell transplantation for multiple myeloma. N Engl J Med, 354, pp. 1021-1030.